Hong Kong’s capital markets are riding a wave of innovation-led IPOs, with over $12.8 B raised in H1 2025. A new pipeline exceeding 160 filings includes a growing number of tech and biotech companies, thanks to initiatives like HKEX’s Tech board.
Significantly, investor appetite has gravitated toward emerging sectors, with 67 biotech IPOs expanding Hong Kong’s equity landscape and AI, healthcare, and telecoms becoming key market drivers. Meanwhile, a confidential Shein filing suggests fintech and e-commerce could propel another blockbuster IPO.
Technology companies are also drawing greater investor attention—Nasdaq may lead U.S. IPOs, but Hong Kong is fast becoming Asia’s biotech and IT capital-raising hub amid rising Chinese interest in offshore investment .
